Scapho Dosage/Direction for Use

Dosage regimen: Adult plaque psoriasis: The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3, and 4 followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Pediatric plaque psoriasis: The recommended dose is based on body weight (Table 11) and administered by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 75 mg dose is given as one subcutaneous injection of 75 mg. Each 150 mg dose is given as one subcutaneous injection of 150 mg. Each 300 mg dose is given as two subcutaneous injections of 150 mg. (See Table 11.)

Click on icon to see table/diagram/image

Psoriatic arthritis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg.
For patients who are anti-TNFα inadequate responders (IR) or patients with concomitant moderate to severe plaque psoriasis, the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing.
Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Axial spondyloarthritis (axSpA): Ankylosing spondylitis (AS): The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3, and 4 followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg.
Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Non-radiographic axial spondyloarthritis (nr-axSpA): The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3, and 4 followed by monthly maintenance dosing.
Special populations: Renal impairment/hepatic impairment: No studies specifically in these patient populations.
Pediatric patients: Safety and effectiveness in pediatric patients with plaque psoriasis below the age of 6 years have not been established.
Safety and effectiveness in pediatric patients below the age of 18 years in other indications have not yet been established.
Geriatric patients (65 years or above): No dose adjustment is required.
Method of administration: Powder for solution for injection: Administered by subcutaneous injection. Reconstitute before use. Full instructions for use are provided in INSTRUCTIONS FOR USE AND HANDLING under Cautions for Usage.
Pre-filled pen: Administered by subcutaneous injection. If possible, areas of the skin that show psoriasis should be avoided as injection sites.
After proper training in subcutaneous injection technique, patients may self-inject or be injected by a caregiver if a physician determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Patients and/or caregivers should be instructed to inject the full amount according to the instructions provided in the package leaflet. Comprehensive instructions for administration are given in the package leaflet.
Full instructions for use are provided in INSTRUCTIONS FOR USE AND HANDLING under Cautions for Usage.